Zacks: Analysts Anticipate Ascendis Pharma A/S (ASND) Will Post Earnings of -$0.97 Per Share

Wall Street analysts forecast that Ascendis Pharma A/S (NASDAQ:ASND) will post earnings of ($0.97) per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for Ascendis Pharma A/S’s earnings, with the lowest EPS estimate coming in at ($1.00) and the highest estimate coming in at ($0.93). Ascendis Pharma A/S posted earnings of ($0.55) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 76.4%. The firm is expected to announce its next quarterly earnings results after the market closes on Wednesday, March 28th.

On average, analysts expect that Ascendis Pharma A/S will report full-year earnings of ($4.22) per share for the current fiscal year, with EPS estimates ranging from ($4.25) to ($4.18). For the next financial year, analysts forecast that the firm will post earnings of ($3.22) per share, with EPS estimates ranging from ($3.86) to ($2.86). Zacks’ EPS averages are an average based on a survey of analysts that that provide coverage for Ascendis Pharma A/S.

How to Become a New Pot Stock Millionaire

A number of brokerages recently commented on ASND. Credit Suisse Group reaffirmed a “hold” rating and issued a $50.00 price target on shares of Ascendis Pharma A/S in a report on Tuesday. Zacks Investment Research raised shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Thursday, March 1st. Wedbush reaffirmed an “outperform” rating and issued a $62.00 price target on shares of Ascendis Pharma A/S in a report on Tuesday, February 6th. BidaskClub raised shares of Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a report on Wednesday, December 27th. Finally, JPMorgan Chase & Co. reaffirmed a “buy” rating and issued a $60.00 price target on shares of Ascendis Pharma A/S in a report on Wednesday, January 17th. Four research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $52.67.

Institutional investors have recently bought and sold shares of the stock. Victory Capital Management Inc. purchased a new stake in Ascendis Pharma A/S in the 3rd quarter worth about $194,000. Aperio Group LLC purchased a new stake in Ascendis Pharma A/S in the 3rd quarter worth about $241,000. Quantitative Systematic Strategies LLC purchased a new stake in Ascendis Pharma A/S in the 4th quarter worth about $269,000. Jane Street Group LLC purchased a new stake in Ascendis Pharma A/S in the 3rd quarter worth about $352,000. Finally, Citadel Advisors LLC purchased a new stake in Ascendis Pharma A/S in the 3rd quarter worth about $372,000. 73.48% of the stock is currently owned by institutional investors.

Shares of Ascendis Pharma A/S (ASND) traded up $1.15 during trading hours on Friday, hitting $64.15. 12,950 shares of the company were exchanged, compared to its average volume of 206,173. Ascendis Pharma A/S has a 1 year low of $21.95 and a 1 year high of $69.00. The company has a market cap of $2,649.22, a P/E ratio of -17.31 and a beta of 0.68.

TRADEMARK VIOLATION WARNING: “Zacks: Analysts Anticipate Ascendis Pharma A/S (ASND) Will Post Earnings of -$0.97 Per Share” was first posted by Stock Observer and is the sole property of of Stock Observer. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this news story can be read at https://www.thestockobserver.com/2018/03/20/zacks-analysts-anticipate-ascendis-pharma-a-s-asnd-will-post-earnings-of-0-97-per-share.html.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.

Get a free copy of the Zacks research report on Ascendis Pharma A/S (ASND)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply